Core Insights - Stryker has received 510(k) clearance from the U.S. FDA for its OptaBlate basivertebral nerve ablation system, which targets the basivertebral nerve to provide long-lasting relief from chronic vertebrogenic low back pain [2][3] - The OptaBlate BVN system is part of Stryker's advanced pain therapy solutions and combines radiofrequency ablation technology with vertebral access [2][3] - The introduction of OptaBlate BVN aims to address the needs of patients suffering from chronic low back pain who have not found relief through traditional treatments [3][5] Product Features - The OptaBlate BVN system achieves at least a 1 cm lesion in 7 minutes, utilizing a steerable, dynamic curved introducer for targeted performance [7] - It incorporates microinfusion technology to keep the treatment zone hydrated, reducing impedance errors and preventing charring [7] - The system includes 10-gauge access tools to facilitate the procedure [7] Market Introduction - Stryker plans to showcase the OptaBlate BVN at the American Society of Pain & Neuroscience (ASPN) Annual Meeting scheduled for July 17-20 in Miami, FL [3]